首页> 外文OA文献 >Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: The role of viral membrane fusion activity
【2h】

Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: The role of viral membrane fusion activity

机译:整个灭活病毒疫苗诱导的异型交叉保护对流感的感染:病毒膜融合活性的作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Background: The inability of seasonal influenza vaccines to effectively protect against infection with antigenically drifted viruses or newly emerging pandemic viruses underlines the need for development of cross-reactive influenza vaccines that induce immunity against a variety of virus subtypes. Therefore, potential cross-protective vaccines, e.g., whole inactivated virus (WIV) vaccine, that can target conserved internal antigens such as the nucleoprotein (NP) and/or matrix protein (M1) need to be explored. Methodology/Principal Findings: In the current study we show that a WIV vaccine, through induction of cross-protective cytotoxic T lymphocytes (CTLs), protects mice from heterosubtypic infection. This protection was abrogated after depletion of CD8+ cells in vaccinated mice, indicating that CTLs were the primary mediators of protection. Previously, we have shown that different procedures used for virus inactivation influence optimal activation of CTLs by WIV, most likely by affecting the membrane fusion properties of the virus. Specifically, inactivation with formalin (FA) severely compromises fusion activity of the virus, while inactivation with β-propiolactone (BPL) preserves fusion activity. Here, we demonstrate that vaccination of mice with BPL-inactivated H5N1 WIV vaccine induces solid protection from lethal heterosubtypic H1N1 challenge. By contrast, vaccination with FA-inactivated WIV, while preventing death after lethal challenge, failed to protect against development of disease and severe body weight loss. Vaccination with BPL-inactivated WIV, compared to FA-inactivated WIV, induced higher levels of specific CD8+ T cells in blood, spleen and lungs, and a higher production of granzyme B in the lungs upon H1N1 virus challenge. Conclusion/Significance: The results underline the potential use of WIV as a cross-protective influenza vaccine candidate. However, careful choice of the virus inactivation procedure is important to retain membrane fusion activity and full immunogenicity of the vaccine. © 2012 Budimir et al.
机译:背景:季节性流感疫苗无法有效地防止抗原性漂移病毒或新出现的大流行性病毒感染,因此需要开发交叉反应型流感疫苗,以诱导针对多种病毒亚型的免疫力。因此,需要研究可以靶向保守的内部抗原例如核蛋白(NP)和/或基质蛋白(M1)的潜在交叉保护疫苗,例如全灭活病毒(WIV)疫苗。方法/主要发现:在当前研究中,我们表明WIV疫苗通过诱导交叉保护性细胞毒性T淋巴细胞(CTL)来保护小鼠免受异型感染。接种小鼠的CD8 +细胞枯竭后,该保护被取消,表明CTL是保护的主要介质。以前,我们已经表明,用于病毒灭活的不同程序会通过WIV影响CTL的最佳激活,最有可能通过影响病毒的膜融合特性来实现。具体而言,用福尔马林(FA)灭活会严重损害病毒的融合活性,而用β-丙内酯(BPL)灭活则会保留融合活性。在这里,我们证明了用BPL灭活的H5N1 WIV疫苗对小鼠进行疫苗接种可诱导免受致命的亚型H1N1挑战的固体保护。相比之下,用FA灭活的WIV进行疫苗接种虽然可以防止致死性攻击后死亡,但却无法预防疾病的发展和严重的体重减轻。与FA灭活的WIV相比,用BPL灭活的WIV进行疫苗接种可诱导血液,脾脏和肺中更高水平的特异性CD8 + T细胞水平,以及在H1N1病毒攻击后在肺中产生更高的颗粒酶B。结论/意义:结果强调了将WIV作为交叉保护性流感疫苗候选物的潜在用途。但是,仔细选择病毒灭活程序对于保持膜融合活性和疫苗的完全免疫原性很重要。 ©2012 Budimir等人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号